Integrated Genomic Analyses of Ovarian Carcinoma

@article{Bell2011IntegratedGA,
  title={Integrated Genomic Analyses of Ovarian Carcinoma},
  author={D. Bell and A. Berchuck and M. Birrer and J. Chien and D. Cramer and F. Dao and R. Dhir and P. Disaia and H. Gabra and Pat Glenn and A. Godwin and J. Gross and L. Hartmann and M. Huang and D. Huntsman and M. Iacocca and M. Imieliński and S. Kalloger and B. Karlan and D. Levine and G. Mills and C. Morrison and D. Mutch and Narciso Olvera and S. Orsulic and K. Park and N. Petrelli and B. Rabeno and J. Rader and B. Sikic and K. Smith-McCune and A. Sood and D. Bowtell and R. Penny and J. Testa and K. Chang and H. Dinh and J. Drummond and G. Fowler and P. Gunaratne and A. Hawes and C. Kovar and L. Lewis and M. Morgan and I. Newsham and J. Santibanez and J. Reid and L. Trevi{\~n}o and Y. Q. Wu and M. Wang and D. Muzny and D. Wheeler and R. Gibbs and G. Getz and M. Lawrence and K. Cibulskis and A. Sivachenko and C. Sougnez and Douglas Voet and Jane Wilkinson and T. Bloom and K. Ardlie and T. Fennell and J. Baldwin and S. Gabriel and E. Lander and L. Ding and R. Fulton and D. Koboldt and M. McLellan and T. Wylie and Jason R. Walker and M. O'Laughlin and D. Dooling and L. Fulton and R. Abbott and N. Dees and Q. Zhang and C. Kandoth and M. Wendl and W. Schierding and D. Shen and C. C. Harris and H. Schmidt and J. Kalicki and K. Delehaunty and C. Fronick and R. Demeter and L. Cook and J. Wallis and L. Lin and V. Magrini and J. Hodges and J. Eldred and S. M. Smith and C. Pohl and Fabio Vandin and Benjamin J. Raphael and G. Weinstock and E. Mardis and Richard K. Wilson and M. Meyerson and W. Winckler and R. Verhaak and Suzie Carter and C. Mermel and G. Saksena and H. Nguyen and R. Onofrio and D. Hubbard and S. Gupta and A. Crenshaw and A. Ramos and L. Chin and A. Protopopov and Juinhua Zhang and T. Kim and I. Perna and Y. Xiao and Hailei Zhang and G. Ren and N. Sathiamoorthy and R. Park and E. Lee and P. Park and R. Kucherlapati and D. Absher and L. Waite and G. Sherlock and J. Brooks and J. Li and Jin Xu and R. Myers and P. Laird and L. Cope and J. Herman and Hui Shen and D. Weisenberger and H. Noushmehr and F. Pan and T. Triche and B. Berman and D. V. Berg and J. Buckley and S. Baylin and P. Spellman and E. Purdom and P. Neuvial and H. Bengtsson and L. Jakkula and S. Durinck and J. Han and S. Dorton and H. Marr and Y. Choi and V. Wang and N. Wang and J. Ngai and J. Conboy and B. Parvin and H. Feiler and T. Speed and J. Gray and N. Socci and Yanke Liang and B. Taylor and N. Schultz and L. Borsu and A. Lash and C. Brennan and A. Viale and C. Sander and M. Ladanyi and K. Hoadley and S. Meng and Y. Du and Yufeng Shi and Lulin Li and Y. Turman and D. Zang and E. Helms and S. Balu and X. Zhou and Jinhua Wu and M. D. Topal and D. Hayes and C. Perou and Junihua Zhang and Chaowei Wu and S. Shukla and R. Jing and Yueh-Feng Liu and M. Noble and H. Carter and D. Kim and R. Karchin and J. Korkola and Laura M. Heiser and R. Cho and Zhihao Hu and E. Cerami and A. Olshen and B. Reva and Yevgeniy Antipin and R. Shen and P. Mankoo and R. Sheridan and G. Ciriello and William K. Chang and J. Bernanke and D. Haussler and C. Benz and Joshua M. Stuart and S. Benz and J. Z. Sanborn and Charles J. Vaske and J. Zhu and C. Szeto and G. Scott and C. Yau and M. Wilkerson and N. Zhang and R. Akbani and K. Baggerly and W. Yung and J. Weinstein and T. Shelton and D. Grimm and Martha Hatfield and S. Morris and P. Yena and P. Rhodes and M. Sherman and J. Paulauskis and S. Millis and A. Kahn and J. Greene and R. Sfeir and M. Jensen and James K. Chen and J. Whitmore and S. Alonso and J. Jordan and A. Chu and Jinghui Zhang and A. Barker and C. Compton and G. Eley and M. Ferguson and P. Fielding and D. Gerhard and R. Myles and C. Schaefer and K. Shaw and J. Vaught and J. Vockley and P. Good and M. Guyer and B. Ozenberger and James Peterson and E. Thomson},
  journal={Nature},
  year={2011},
  volume={474},
  pages={609 - 615}
}
A catalogue of molecular aberrations that cause ovarian cancer is critical for developing and deploying therapies that will improve patients’ lives. The Cancer Genome Atlas project has analysed messenger RNA expression, microRNA expression, promoter methylation and DNA copy number in 489 high-grade serous ovarian adenocarcinomas and the DNA sequences of exons from coding genes in 316 of these tumours. Here we report that high-grade serous ovarian cancer is characterized by TP53 mutations in… Expand

Paper Mentions

Observational Clinical Trial
The study aims to develop a test for early detection of ovarian cancer using DNA from a growth involving the ovary found in a washing of the uterus (womb), and proteins found in the… Expand
ConditionsFallopian Tube Neoplasms, High Grade Ovarian Serous Adenocarcinoma, Ovarian Epithelial Carcinoma, (+12 more)
InterventionDiagnostic Test
Interventional Clinical Trial
This trial is a randomized, open-label Phase I-2 multi-center study designed to evaluate the effect of Carboplatin-Paclitaxel-Bevacizumab (in combination and maintenance) vs… Expand
ConditionsAdvanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer
InterventionDrug
Observational Clinical Trial
The aim of the project is to corroborate them on a large retrospective cohort of HGS-EOC and confirm the possibility of identify TP53 mutations in high grade endometrioid tumors… Expand
ConditionsOvarian Cancer
InterventionDiagnostic Test
Interventional Clinical Trial
This study is a phase II clinical trial to evaluate the safety and efficacy of Bortezomib plus Pegylated liposomal doxorubicin combination therapy in a histologic type of high-grade… Expand
ConditionsHigh Grade Serous Carcinoma, Ovarian Neoplasm Epithelial
InterventionDrug
Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice
TLDR
Gene mutations, copy number aberrations and DNA methylations provided promising biomarkers for the detection, diagnosis, prognosis, therapy response and targets of ovarian cancer, and underscore the necessity to translate these potential biomarkers into clinical practice. Expand
Integrated genomic characterization of endometrial carcinoma
  • D. Levine, Gad Stacey B. Kristian Eric Andrey Carrie Mike Cyriac Getz Gabriel Cibulskis Lander Sivachenko Sougnez L, +271 authors H. Sofia
  • Biology, Medicine
  • Nature
  • 2013
TLDR
The genomic features of endometrial carcinomas permit a reclassification that may affect post-surgical adjuvant treatment for women with aggressive tumours, and these features are classified into four categories: POLE ultramutated, microsatellite instability hypermutated, copy- number low, and copy-number high. Expand
DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas
TLDR
Somatic alterations occurring in the development of familial EOCs do not differ substantially from the ones occurring in sporadic carcinomas, however, some specific features like extensive genomic loss observed in BRCA1/2 tumours may be of clinical relevance helping to identify BRCa-related patients likely to respond to PARP inhibitors. Expand
Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes
TLDR
This work establishes the potency of the somatic genome, reflective of diverse DNA repair deficiencies, to stratify ovarian cancers into distinct biological strata within the major histotypes. Expand
Comprehensive molecular portraits of human breast tumors
TLDR
The ability to integrate information across platforms provided key insights into previously defined gene expression subtypes and demonstrated the existence of four main breast cancer classes when combining data from five platforms, each of which shows significant molecular heterogeneity. Expand
Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.
TLDR
Optimal prediction models for treatments targeting DNA repair will need to integrate multiples of these genomic signatures and will also need to assess multiple resistance mechanisms such as genomic reversion events that partially or fully re-activate DNA repair. Expand
The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer
TLDR
The BRCAness phenotype is present in almost one-fourth of epithelial ovarian carcinoma and holds important prognostic information, and was associated with improved overall survival in the high-grade serous carcinoma subgroup. Expand
Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells
TLDR
Ovarian cancer cells have an intrinsic plasticity, thus explaining that in a single tumor more than one cell subpopulation, may exhibit tumor-initiating capacity, and improvements in the understanding of the molecular and cellular basis of ovarian cancers should lead to more efficacious treatments. Expand
Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response.
TLDR
Comparison of DNA copy number changes in tumors with or without BRCA1/BRCA2 alterations, lead to the identification of several signatures that detect HR pathway defects, here named "HRness". Expand
Genome Wide DNA Copy Number Analysis of Serous Type Ovarian Carcinomas Identifies Genetic Markers Predictive of Clinical Outcome
TLDR
A set of genetic alterations that could be used for stratification of high-grade serous tumors into clinically relevant treatment subgroups is identified and identified 8 genomic regions that are distinctly different among the subgroups. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 87 REFERENCES
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
TLDR
The interim integrative analysis of DNA copy number, gene expression and DNA methylation aberrations in 206 glioblastomas reveals a link between MGMT promoter methylation and a hypermutator phenotype consequent to mismatch repair deficiency in treated gliobeasts, demonstrating that it can rapidly expand knowledge of the molecular basis of cancer. Expand
Somatic mutations affect key pathways in lung adenocarcinoma
TLDR
Somatic mutations in primary lung adenocarcinoma for several tumour suppressor genes involved in other cancers and for sequence changes in PTPRD as well as the frequently deleted gene LRP1B are found. Expand
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
BACKGROUND Inherited mutations in the BRCA1 gene may be responsible for almost half of inherited breast carcinomas. However, somatic (acquired) mutations in BRCA1 have not been reported, despiteExpand
Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas
TLDR
Two distinct mechanisms of primary treatment failure in serous ovarian cancer are identified, involving CCNE1 amplification and enhanced extracellular matrix deposition, andCCNE1 copy number is validated as a dominant marker of patient outcome in ovarian cancer. Expand
The landscape of somatic copy-number alteration across human cancers
TLDR
It is demonstrated that cancer cells containing amplifications surrounding the MCL1 and BCL2L1 anti-apoptotic genes depend on the expression of these genes for survival, and a large majority of SCNAs identified in individual cancer types are present in several cancer types. Expand
ARID1A mutations in endometriosis-associated ovarian carcinomas.
TLDR
These data implicate ARID1A as a tumor-suppressor gene frequently disrupted in ovarian clear-cell and endometrioid carcinomas. Expand
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
TLDR
It is concluded that mutant TP53 is a driver mutation in the pathogenesis of HGPSC cancers because it is almost invariably present in HGPSCs, and is not of substantial prognostic or predictive significance. Expand
p53 mutation is infrequent in clear cell carcinoma of the ovary.
TLDR
Mutations in p53 appear to be much less frequent in clear cell carcinoma than in other histologic types of epithelial ovarian cancer, and it is suggested that p53 alterations may not play an important role in the development of clear cell cancer. Expand
Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM)
TLDR
Over 20,000 genes were recently sequenced in a series of 24 pancreatic cancers and CHASM identified putative driver mutations in three known pancreatic cancer driver genes (P53, SMAD4, CDKN2A), which point to potential "driver genes" in pancreaticcancer that should be prioritized for additional follow-up. Expand
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
TLDR
A robust gene expression-based molecular classification of GBM into Proneural, Neural, Classical, and Mesenchymal subtypes is described and multidimensional genomic data is integrated to establish patterns of somatic mutations and DNA copy number. Expand
...
1
2
3
4
5
...